

NOV. 16 2005 10:16AM AVENTIS US PAT DEPT

NO. 9797 P. 5

Please type a plus sign (+) inside this box →

PTO/SABBA (10-86)

Approved for use through 10/31/99. OMB 0651-0031

PATENT AND TRADEMARK OFFICE: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/636,001
		Filing Date	08-07-2003
		First Named Inventor	STROBEL
		Group Art Unit	1626
		Examiner Name	GRAZIER, N.
Sheet	1	of	1
		Attorney Docket Number	DEAV2002/0058 - US - NP

Examiner Signature	Nicole L. Sosa	Date Considered	3/1/06
-----------------------	----------------	--------------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documenta. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/636,001
(use as many sheets as necessary)				Filing Date	August 7, 2003
				First Named Inventor	STROBEL, et al.
				Group Art Unit	
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	DEAV2002/0058 - US - NP



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Completer if Known

Application Number	10/636,001
Filing Date	August 7, 2003
First Named Inventor	STROBEL, et al.
Group Art Unit	
Examiner Name	

Attorney Docket Number DEAV2002/0058 - US - NP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
JK		EP	0237028	A1	VASSIL, et al.	09-16-1987	
JK		WO	02/064146	A1	STROBEL, et al.	08-22-2002	
JK		WO	02/064545	A1	STROBEL, et al.	08-22-2002	
JK		WO	02/064546	A2	STROBEL, et al.	08-22-2002	
JK		WO	02/064565	A1	STROBEL et al.	08-22-2002	
JK		WO	W000/03746	A2	LIAO	01-27-2000	
JK		WO	W002/20530	A1	BARTLETT, et al.	03-14-2002	
JK		WO	W098/36749	A1	AHMAD, et al.	08-27-1998	
JK		WO	W099/47153	A2	LIAO	09-23-1999	

**Examiner
Signature**

Date
Considered

3/1/06


***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

Complaint if Known

Application Number	10/636,001
Filing Date	August 7, 2003
First Named Inventor	STROBEL, et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	DEAV2002/0058 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
MG		AGGARWAL, et al., Catalytic Cyclopropanation Of Alkenes Using Diazo Compounds Generated In Situ. A Novel Route To 2-Arylcyclopropylamines, Org. Letters, 2001, 3 (17) 2785-2788
MG		BROWN, et al., Organoboranes For Synthesis 7. An Improved General Synthesis of Primary Amines From Alkenes via Hydroboration-Organoborane Chemistry, Tetrahedron, 1987, 43 (18), 4071-4078
MG		COUTTS, et al., Neurochemical and Neuropharmacological Properties of 4-Fluorotranlycypromine, Cell. Mol. Neurobiol., 1987, 7 (3), 271-291
MG		ENDRES, et al., Stroke Protection By 3-hydroxy-3-methylglutaryl (HMG)-CoA Reductase Inhibitors Mediated By Endothelial Nitric Oxide Synthase, Proc. Natl. Acad. Sci. USA, 1998, 95, 8880-8885
MG		LI, et al., Activation Of Protein Kinase Ca and or e Enhances Transcription of the Human Endothelial Nitric Oxide Synthase Gene, Mol. Pharmacol., 1998, 53, 630-637
MG		MOROI, et al., Interaction Of Genetic Deficiency Of Endothelial Nitric Oxide, Gender, and Pregnancy In Vascular Response To Injury In Mice, J. Clin. Invest., 1998, 101 (6), 1225-1232
MG		NAKAYAMA, et al., T-786- C Mutation in the 5' -Flanking Region Of The Endothelial Nitric Oxide Synthase Gene Is Associated With Coronary Spasm, Circulation, 1999, 99, 2864-2870
MG		SESSA, et al., Chronic Exercise In Dogs Increases Coronary Vascular Nitric Oxide Production And Endothelial Cell Nitric Oxide Synthase Gene Expression, Circ. Research, 1994, 74, 349-353
MG		VARENNE, et al., Percutaneous Gene Therapy Using Recombinant Adenoviruses Encoding Human Herpes Simplex Virus Thymidine Kinase, Human PAI-1, and Human NOS3 in Balloon-Injured Porcine Coronary Arteries, Hum. Gene Ther. 2000, 11, 1329-1339
MG		WIEHL, et al., Synthese Und Absolute Konfiguration 2-Substituierter Cyclopentanamine, Chem. Ber. 1986, 119, 2668-2677

Examiner Signature

Date Considered

3/1/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.